MicroPEA: an essential component of modern PEA formulations!
MicroPEA is the content of special patented PEA formulations. Only these formulations have a long trackrecord of safety and efficacy.
In 2016 an all-encompassing safety review was published on modern PEA formulations, gathered together under the denominator microPEA.
Micro-PEA contains small, fine and ultrafine PEA particles
Micro-PEA is based on a special patented formulations containing small, fine and ultrafine PEA particles (in literature fine and ultrafine PEA particles are referred to as um-PEA (ultramicronized PEA), m-PEA (micronized PEA) or as PEA-opt (optimized PEA).
Micro-PEA containing formulations are key for safety, efficacy and biological effects!
For all ultra fine PEA formulations the patent holders (e.g. Innovet, een Italiaans bedrijf and Russell Science) have pointed out that such formulations are characterized by:
- Long term safety data in a great number of patients
- Efficacy in various disorders characterized by chronic pain and inflammation, based on data published in peer reviewed journals: clinical trials, case report collections and case-reports
- A clear and measurable increase in endogenous PEA levels after intake of PEA tablets or PEA capsules (Russell Science) (see picture below). The data are based on relative few measurements, as can be seen (arrows of confidence limit), and both formulations are comparable.
MicroPEA in leading formulatrions (in um-PEA and PEA-opt) gives rise to measurable increases of PEA plasma levels
In 2016 an imoressive review was published proving extensively the safety profile of such formulations, by Dr Earle R. Nestmann in an article on microPEA:
Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential (Source:Food Science & Nutrition 2016: 1-18)
Dr Nestmann explored in great detail the safety profile of Micro-PEA and stated:
The results of the new toxicological studies described in this study show that microPEA has a favorable safety pro le for its use in health products intended for human and companion animal consumption, with a no effect level in repeated dose studies that is >1000 mg/kg bw.
These results are in agreement with earlier studies done with PEA by the then Czechoslovakia Academy of Sciences that were not published but are described in the review by Masek (1980).
For more information see:
The Natural Pea: Supplements containing micro- palmitoylethanolamide (micro-PEA). A breakthrough.